Traumatic Brain Injury (TBI) is a significant health issue and is frequently complicated by the development of epilepsy. There are currently no clinically proven preventive or disease modifying therapies for post-traumatic epilepsy (PTE) and anticonvulsants have consistently failed to prevent epileptogenesis, the pathological process that leads to the development and progression of spontaneous recurrent epileptic seizures.
A substantial body of evidence supports a key role for inflammation in epileptogenesis. It is also well recognised that TBI induces a vigorous inflammatory response through the release of danger signals, molecules that help to recruit immune cells to the site of injury and to activate them. This PhD explores the premise that therapies that block danger signalling may prevent or ameliorate post-traumatic epilepsy. The project will use a combination of imaging and inflammatory molecule profiling in a preclinical model of TBI and PTE to assess a novel monoclonal antibody therapy. The candidate should be enthusiastic about learning new techniques and be able to work both independently and in a team environment.
A working knowledge of molecular biology, animal handling and imaging (MRI, PET) would be of benefit to someone working on this project.